Jennifer N. Brudno

10.1k total citations · 7 hit papers
28 papers, 3.5k citations indexed

About

Jennifer N. Brudno is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Jennifer N. Brudno has authored 28 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 10 papers in Molecular Biology and 7 papers in Immunology. Recurrent topics in Jennifer N. Brudno's work include CAR-T cell therapy research (23 papers), Viral Infectious Diseases and Gene Expression in Insects (9 papers) and Virus-based gene therapy research (6 papers). Jennifer N. Brudno is often cited by papers focused on CAR-T cell therapy research (23 papers), Viral Infectious Diseases and Gene Expression in Insects (9 papers) and Virus-based gene therapy research (6 papers). Jennifer N. Brudno collaborates with scholars based in United States, India and Israel. Jennifer N. Brudno's co-authors include James N. Kochenderfer, David F. Stroncek, Ronald E. Gress, Jeremy J. Rose, Brenna Hansen, Maryalice Stetler‐Stevenson, Irina Marić, Victoria Shi, Steven A. Feldman and Michael Wang and has published in prestigious journals such as JAMA, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Jennifer N. Brudno

27 papers receiving 3.5k citations

Hit Papers

Toxicities of chimeric antigen receptor T cells: recognit... 2016 2026 2019 2022 2016 2018 2016 2017 2024 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Toxicities of chimeric antigen receptor T cells: recognition and management
    2016 988 citations Jennifer N. Brudno, James N. Kochenderfer Blood profile →
  2. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
    2018 631 citations Jennifer N. Brudno, James N. Kochenderfer Blood Reviews profile →
  3. T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
    2016 596 citations Syed Abbas Ali, Victoria Shi et al. Blood profile →
  4. Chimeric antigen receptor T-cell therapies for lymphoma
    2017 375 citations Jennifer N. Brudno, James N. Kochenderfer Nature Reviews Clinical Oncology profile →
  5. Current understanding and management of CAR T cell-associated toxicities
    2024 98 citations Jennifer N. Brudno, James N. Kochenderfer Nature Reviews Clinical Oncology profile →
  6. CAR T Cells and T-Cell Therapies for Cancer
    2024 86 citations Jennifer N. Brudno, Marcela V. Maus et al. JAMA profile →
  7. Chimeric antigen receptor T cell therapy for autoimmune disease
    2024 52 citations James Chung, Jennifer N. Brudno et al. Nature reviews. Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jennifer N. Brudno United States 19 2.9k 1.0k 928 877 730 28 3.5k
Bianca Santomasso United States 19 3.2k 1.1× 779 0.8× 764 0.8× 653 0.7× 683 0.9× 46 3.7k
Chrystal U. Louis United States 20 3.5k 1.2× 1.1k 1.1× 1.3k 1.4× 801 0.9× 1.1k 1.5× 56 4.6k
Elena Mead United States 10 2.1k 0.7× 556 0.5× 524 0.6× 558 0.6× 597 0.8× 25 2.4k
Saad S. Kenderian United States 25 2.1k 0.7× 737 0.7× 790 0.9× 537 0.6× 647 0.9× 149 2.9k
Olalekan O. Oluwole United States 25 2.1k 0.7× 604 0.6× 508 0.5× 393 0.4× 428 0.6× 154 2.4k
Sherry Adkins United States 9 1.9k 0.6× 451 0.4× 503 0.5× 543 0.6× 472 0.6× 14 2.1k
Frederick L. Locke United States 34 5.2k 1.8× 1.4k 1.4× 1.4k 1.5× 1.2k 1.3× 1.2k 1.6× 307 6.0k
Craig S. Sauter United States 29 3.4k 1.2× 777 0.8× 973 1.0× 689 0.8× 830 1.1× 189 4.7k
Barbara Camisa Italy 13 1.8k 0.6× 598 0.6× 1.2k 1.3× 518 0.6× 533 0.7× 27 2.6k
Caron A. Jacobson United States 32 2.6k 0.9× 790 0.8× 835 0.9× 442 0.5× 499 0.7× 215 3.8k

Countries citing papers authored by Jennifer N. Brudno

Since Specialization
Citations

This map shows the geographic impact of Jennifer N. Brudno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer N. Brudno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer N. Brudno more than expected).

Fields of papers citing papers by Jennifer N. Brudno

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer N. Brudno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer N. Brudno. The network helps show where Jennifer N. Brudno may publish in the future.

Co-authorship network of co-authors of Jennifer N. Brudno

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer N. Brudno. A scholar is included among the top collaborators of Jennifer N. Brudno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer N. Brudno. Jennifer N. Brudno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
McIntyre, Lori, Stephanie L. Goff, James C. Yang, et al.. (2025). Survival after anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma and CLL with 10 years of follow-up. Blood Advances. 9(20). 5362–5366.
2.
Brudno, Jennifer N. & James N. Kochenderfer. (2024). Current understanding and management of CAR T cell-associated toxicities. Nature Reviews Clinical Oncology. 21(7). 501–521. 98 indexed citations breakdown →
3.
Chung, James, Jennifer N. Brudno, Dominic Borie, & James N. Kochenderfer. (2024). Chimeric antigen receptor T cell therapy for autoimmune disease. Nature reviews. Immunology. 24(11). 830–845. 52 indexed citations breakdown →
4.
Brudno, Jennifer N., Marcela V. Maus, & Christian S. Hinrichs. (2024). CAR T Cells and T-Cell Therapies for Cancer. JAMA. 332(22). 1924–1924. 86 indexed citations breakdown →
5.
Brudno, Jennifer N., Nisha Patel, Roberto Maass‐Moreno, et al.. (2023). Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial. Blood Advances. 8(3). 802–814. 12 indexed citations
6.
Ligon, John A., Seth M. Steinberg, Toni Foley, et al.. (2022). The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes. Blood Advances. 6(23). 6040–6050. 25 indexed citations
7.
Brudno, Jennifer N., Nisha Patel, Lekha Mikkilineni, et al.. (2022). Transient Responses and Significant Toxicities Due to Cytopenias and Rashes with Anti-CD30 CAR T Cells for CD30-Expressing Lymphomas: Results of a Phase I Clinical Trial. Blood. 140(Supplement 1). 12731–12732. 2 indexed citations
8.
Nussenblatt, Véronique, Allison Roder, Sanchita Basu Das, et al.. (2021). Yearlong COVID-19 Infection Reveals Within-Host Evolution of SARS-CoV-2 in a Patient With B-Cell Depletion. The Journal of Infectious Diseases. 225(7). 1118–1123. 48 indexed citations
9.
Mikkilineni, Lekha, Elisabet E. Manasanch, Jennifer N. Brudno, et al.. (2021). Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity. Blood. 138(Supplement 1). 3837–3837. 8 indexed citations
10.
Brudno, Jennifer N., Norris Lam, Danielle Vanasse, et al.. (2020). Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nature Medicine. 26(2). 270–280. 228 indexed citations
11.
12.
Panch, Sandhya R., James Szymanski, Steven L. Highfill, et al.. (2019). Effects of starting cellular material composition on chimeric antigen receptor T‐cell expansion and characteristics. Transfusion. 59(5). 1755–1764. 32 indexed citations
13.
Brudno, Jennifer N. & James N. Kochenderfer. (2018). Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Reviews. 34. 45–55. 631 indexed citations breakdown →
14.
Brudno, Jennifer N. & James N. Kochenderfer. (2017). Chimeric antigen receptor T-cell therapies for lymphoma. Nature Reviews Clinical Oncology. 15(1). 31–46. 375 indexed citations breakdown →
15.
Brudno, Jennifer N. & James N. Kochenderfer. (2016). Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 127(26). 3321–3330. 988 indexed citations breakdown →
16.
Brudno, Jennifer N., Victoria Shi, David Stroncek, et al.. (2016). T Cells Expressing a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor Induce Remissions of Advanced Lymphoma in a First-in-Humans Clinical Trial. Blood. 128(22). 999–999. 27 indexed citations
17.
Brudno, Jennifer N., Tamar Tadmor, Stefania Pittaluga, et al.. (2015). Discordant bone marrow involvement in non-Hodgkin lymphoma. Blood. 127(8). 965–970. 20 indexed citations
18.
Ali, Syed Abbas, Victoria Shi, Michael Wang, et al.. (2015). Remissions of Multiple Myeloma during a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor. Blood. 126(23). LBA–1. 18 indexed citations
19.
Calado, Rodrigo T., Jennifer N. Brudno, Colin O. Wu, et al.. (2011). Constitutional telomerase mutations are genetic risk factors for cirrhosis. Hepatology. 53(5). 1600–1607. 119 indexed citations
20.
Compton, Michael T., et al.. (2007). Facial measurement differences between patients with schizophrenia and non-psychiatric controls. Schizophrenia Research. 93(1-3). 245–252. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bianca Santomasso Breakdown of academic impact, for papers by Chrystal U. Louis Breakdown of academic impact, for papers by Elena Mead Breakdown of academic impact, for papers by Saad S. Kenderian Breakdown of academic impact, for papers by Olalekan O. Oluwole Breakdown of academic impact, for papers by Sherry Adkins Breakdown of academic impact, for papers by Frederick L. Locke Breakdown of academic impact, for papers by Craig S. Sauter Breakdown of academic impact, for papers by Barbara Camisa Breakdown of academic impact, for papers by Caron A. Jacobson
Rankless by CCL
2026